FDA Approves New Acalabrutinib Formulation

On August 5, 2022, the U.S. Food and Drug Administration approved the new tablet formulation for acalabrutinib for all current indications, including chronic lymphocytic leukaemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.

For more information, read AstraZeneca's announcement.

Posted 8/12/2022